Is TIRUMALCHM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TIRUMALCHM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TIRUMALCHM (₹375.6) is trading above our estimate of fair value (₹13.54)
Significantly Below Fair Value: TIRUMALCHM is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TIRUMALCHM?
Key metric: As TIRUMALCHM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for TIRUMALCHM. This is calculated by dividing TIRUMALCHM's market cap by their current
revenue.
What is TIRUMALCHM's PS Ratio?
PS Ratio
1.8x
Sales
₹20.98b
Market Cap
₹38.46b
TIRUMALCHM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
2.3x
Enterprise Value/EBITDA
93.1x
PEG Ratio
n/a
Price to Sales Ratio vs Peers
How does TIRUMALCHM's PS Ratio compare to its peers?
The above table shows the PS ratio for TIRUMALCHM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Price-To-Sales vs Industry: TIRUMALCHM is expensive based on its Price-To-Sales Ratio (1.8x) compared to the Indian Chemicals industry average (1.8x).
Price to Sales Ratio vs Fair Ratio
What is TIRUMALCHM's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
TIRUMALCHM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
1.8x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate TIRUMALCHM's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.